All In Biotech

Drug Trial Radar · NCT06869187

Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults

A Phase 2 Open-label Study of the Effect of Adjunctively Administered ABX-002 in Adults With Bipolar Disorder Experiencing an Episode of Depression

Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Mar 28, 2025

Primary completion

Apr 22, 2026

Study completion Sep 24, 2026

Sponsor

Lead sponsor
Autobahn Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment(s) can improve clinical symptoms of depression and to learn about potential effects on brain chemistry that may correlate with antidepressive effects. This is a single treatment arm, open-label, Phase 2 study of ABX-002 in up to30 adults with bipolar depression. A subset of these participants will undergo brain imaging. Five healthy volunteer participants will also be enrolled and receive no drug treatment, undergoing 2 imaging sessions to confirm instrument and test - retest method reliability control. For bipolar disorder participants who are experiencing an episode of depression, the study will include 4 study periods: 1. Screening Period of up to 5 weeks 2. 6-week Treatment Period 3. 2-week post dose Safety Follow-up Period. 4. 6-month postdose targeted safety follow-up period For healthy volunteers, the study will include 2 study periods: 1. Screening Period of up to 3 weeks 2. Imaging Period of up to 3 weeks.

Conditions

  • Bipolar Disorder Depression

Interventions

  • ABX-002Drug

    ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline for 17-item Hamilton Rating Scale for Depression (HAMD-17)Time frame: Weeks 6

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Autobahn Site #213

    Walnut Creek, California

  • Autobahn Site #201

    Cromwell, Connecticut

  • Autobahn Site #210

    Hartford, Connecticut

  • Autobahn Site #212

    Miami, Florida

  • Autobahn Site #215

    Chicago, Illinois

  • Autobahn Site #216

    Worcester, Massachusetts

  • Autobahn Site #208

    Cherry Hill, New Jersey

  • Autobahn Site #209

    Hamilton, New Jersey

  • Autobahn Site #205

    Marlton, New Jersey

  • Autobahn Site #203

    Brooklyn, New York

  • Autobahn Site #207

    New York, New York

  • Autobahn Site #211

    New York, New York

  • Autobahn Site #204

    Staten Island, New York

  • Autobahn Site #214

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.